Immutep Shares Fall After Recommendation to Shut Down Lung Cancer Therapy Trial
MT Newswires Live
Mar 13
Immutep (IMMP) shares fell 79% in premarket trading Friday after the company said that an independent data monitoring committee has recommended the discontinuation of a phase 3 trial evaluating eftilagimod alfa as a first line treatment for non-small cell lung cancer.
"Based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility," Immutep said.
The company said enrolment in the study would be halted and the trial would be wound down.
Following the discontinuation, Immutep said it now expects its cash runway to extend beyond its previous guidance of Q2 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.